Aligos Therapeutics downgraded by Jefferies
$ALGS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Jefferies downgraded Aligos Therapeutics from Buy to Hold
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/19/2024 | $75.00 | Buy | H.C. Wainwright |
1/6/2023 | $2.00 → $3.00 | Neutral → Overweight | Piper Sandler |
1/6/2023 | $2.50 → $3.00 | Hold → Buy | Jefferies |
3/23/2022 | $15.00 → $4.00 | Overweight → Neutral | Piper Sandler |
3/11/2022 | $47.00 → $15.00 | Overweight | Piper Sandler |
3/11/2022 | $10.00 → $11.00 | Outperform | SVB Leerink |
2/16/2022 | $15.00 → $10.00 | Outperform | SVB Leerink |
1/7/2022 | $30.00 → $12.00 | Overweight → Neutral | JP Morgan |
H.C. Wainwright initiated coverage of Aligos Therapeutics with a rating of Buy and set a new price target of $75.00
Piper Sandler upgraded Aligos Therapeutics from Neutral to Overweight and set a new price target of $3.00 from $2.00 previously
Jefferies upgraded Aligos Therapeutics from Hold to Buy and set a new price target of $3.00 from $2.50 previously
4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)
4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)
4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)